A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
Status:
Active, not recruiting
Trial end date:
2027-11-20
Target enrollment:
Participant gender:
Summary
This is a safety study to determine the recommended dose to test in clinical trials. The
study involves two treatments with 212Pb (212-lead) VMT-α-NET. This is a safety study only;
it will most likely not provide therapeutic benefit.
Phase:
Early Phase 1
Details
Lead Sponsor:
David Bushnell
Collaborators:
Holden Comprehensive Cancer Center National Cancer Institute (NCI) Perspective Therapeutics